Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: Affinity for open and inactivated states

British Journal of Pharmacology

Volumn 128, Issue 2, 1999, Pages 444-450

  Walker, B D ^a,b   Singleton, C B ^a   Bursill, J A ^a   Wyse, K R ^a   Valenzuela, S M ^b   Qiu, M R ^b   Breit, S N ^b   Campbell, T J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Cardiac arrhythmia; Chinese hamster ovary (CHO K1) cell; Cisapride; Human ether a go go related gene (HERG); Torsades de pointes

Indexed keywords

CISAPRIDE; POTASSIUM CHANNEL; POTASSIUM ION; PROKINETIC AGENT;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLARIZATION; DRUG MECHANISM; DRUG POTENCY; GENETIC TRANSFECTION; HEART ARREST; HEART ARRHYTHMIA; HUMAN; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; STEADY STATE; TORSADE DES POINTES;

ANIMALS; CATION TRANSPORT PROTEINS; CHO CELLS; CISAPRIDE; CRICETINAE; DNA-BINDING PROTEINS; ETHER-A-GO-GO POTASSIUM CHANNELS; GASTROINTESTINAL AGENTS; HUMANS; ION CHANNEL GATING; KINETICS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; TEMPERATURE; TRANS-ACTIVATORS;

EID: 0032836817     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702774     Document Type: Article

References (34)

1. AHMAD, S.R. & WOLFE, S.M. (1995). Cisapride and torsades de pointes. Lancet, 345, 508.
2. BARRY, P.H. (1994). JPCale, a software package for calculating liquid junction potential corrections in patch-clamp, intracellular, epithelial and bilayer measurements and for correcting junction potential measurements. J. Neuroscience Methods, 51, 107-116.
3. BRAN, S., MURRAY, W.A., HIRSCH, I.B. & PALMER, J.P. (1995). Long QT syndrome during high dose cisapride. Arch. Intrern. Med., 155, 756-768.
4. CARLSSON, L., AMOS, G.J., ANDERSSON, B., DREWS, L., DUKER, G. & WADSTEDT, G. (1997). Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J. Pharm. Exp. Ther., 282, 220-227.
5. CARMELIET, E. & MUBAGWA, K. (1998). Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. Progress in Physics & Molecular Biology, 70, 1-72.
6. CHOY, A.M., LANG, C.C., CHOMSKY, D.M., RAYOS, G.H., WILSON, J.R. & RODEN, D.M. (1997). Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation, 96, 2149-2154.
7. CURRAN, M.E., SPLAWSKI, I., TIMOTHY, K.W., VINCENT, G.M., GREEN, E.D. & KEATING, M.T. (1995). A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell, 80, 795-803.
8. DROLET, B., KHALIFA, M., DALEAU, P., HAMELIN, B.A. & TURGEON, J. (1998). Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation, 97, 204-210.
9. HOFMEYR, G.J. & SONNENDECKER, E.W.W. (1986), Secretion of the gastrokinetic agent cisapride in human milk. Eur. J. Clin. Pharmacol., 30, 735-736.
10. HOOVER, C.A., CARMICHAEL, J.K., NOLAN, P.E. & MARCUS, F.I. (1996). Cardiac arrest associated with combination cisapride and itraconazole therapy. J. Cardiovasc. Pharmacol. Therapeut., 1, 255-258.
11. KIEHN, J., LACERDA, A.E., WIBLE, B. & BROWN, A.M. (1996). Molecular physiology and pharmacology of HERG. Single channel currents and block by dofetilide. Circulation, 94, 2572-2579.
12. KH, Y. & ITO, T. (1997). Effects of 5-HT4 receptor agonists, Cisapride, Mosapride citrate, and Zacopride, on cardiac action potentials in guinea pig isolated myocytes. J. Cardiovasc. Pharm., 29, 670-675.
13. Kr. Nature, 388, 289-292.
14. - channel by the gastrointestinal prokinetic agent cisapride. Am. J. Physiol., 273, H2534-H2538.
15. MORGAN JR, T.K. & SULLIVAN, M.E. (1992). An overview of class III electrophysiological agents: A new generation of antiarrhythmic therapy. In Progress in Medicinal Chemistry. ed. Ellis, G.P. and Luscomb, D.K. pp. 65-108. Amsterdam: Elsevier Science Publishers.
16. PUISIEUX, F.L., ADAMANTIDIS, M.M., DUMONTIER, H.M. & DUPUIS, B.A. (1996). Cisapride-induced prolongation of cardiac action potential and early afterdepolarisations in rabbit Purkínje fibres. Br. J. Pharmacol., 117, 1377-1379.
17. RAMPE, D., ROY, M.L., DENNIS, A. & BROWN, A. (1997). A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett., 417, 28-32.
18. ROY, M.L., DUMAINE, R. & BROWN, A.M. (1996). HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation, 94, 817-823.
19. Kr potassium channel. Cell, 81, 299-307.
20. + current. J. Gen. Physiol., 96, 195-215.
21. SEUSSBRICH, H., SCHONHERR, R., HEINEMANN, S.H., ATTALI, B. & BUSCH, A.E. (1997). The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in xenopus oocytes. Br. J. Pharmacol., 120, 968-974.
22. SEUSSBRICH, H., WALDEGGAR, S., LANG, F. & BUSCH, A.E. (1996). Blockade of HERG channels expressed in xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett., 385, 77-80.
23. SMITH, P.L., BAUKROWITZ, T. & YELLEN, C. (1996). The inward rectification mechanism of the HERG cardiac potassium channel. Nature, 379, 833-836.
24. SNYDERS, D.J. & CHAUDHARY, A. (1996). High affinity open channel block by dofetilide of HERG expressed in a human cell line. J. Pharmacol. Exp. Ther., 49, 949-955.
25. Kr channel. J. Gen. Physiol., 107, 611-619.
26. + current. Circulation, 96, 3696-3703.
27. UNITED STATES FOOD AND DRUG ADMINISTRATION. (1998). Talk paper. June 29.
28. WALKER, B.D., VALENZUELA, S.M., SINGLETON, C.B., TIE, H., BURSHI., J.A., WYSE, K.R., QIU, M.R., BREIT, S.N. & CAMPBELL, T.J. (1999). Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline malcate. Br. J. Pharmacol., 127, 243-251.
29. WANG, S., LIU, S., MORALES, M., STRAUSS, H.C. & RASMUSSON, R.L. (1997a). A quantitative analysis of the activation and inactivation kinetics of HERG expressed in Xenopus Oocytes. J. Physiol., 502, 45-60.
30. o and C-type inactivation. FEBS Lett., 417, 43-47.
31. WEST, P.D., MARTIN, D.K., BURSILL, J.A., WYSE, K.R. & CAMPBELL, T.J. (1997). Modulation of the electrophysiologic actions of E-4031 and dofetilide by hyperkalacmia and acidosis in rabbit ventricular myocytes. J. Cardiovasc. Pharmacol. Therapeut., 2, 205-212.
32. WISEMAN, L.R. & FAULDS, D. (1994). Cisapride: an update review of its pharmacology and therapeutic efficacy as a prokinetie agent in gastrointestinal motility disorders. Drugs, 47, 116-152.
33. WYSOWSKI, D.K. & BACSANYI, J. (1996). Cisapride and fatal arrhythmias. N. Engl. J. Med., 335, 290-291.
34. YANG, T. & RODEN, D.M. (1996). Extracellular potassium modulation of drug block of IKr: implications for torsades de pointes and reverse use-dependence. Circulation, 93, 407-411.